Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Critical Limb IschemiaBuerger DiseaseThromboangiitis ObliteransAtherosclerosis Obliterans
Interventions
BIOLOGICAL

CLBS12

Intramuscular transfusion of CLBS12.

DRUG

SOC

Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).

Trial Locations (12)

078-8510

Asahikawa Medical University Hospital - 1-1-1 Higashi-2jou, Midorigaoka

Unknown

Fukuoka Sanno Hospital, Fukuoka

Shonan Kamakura General Hospital, Kamakura

Kobe City Medical Center General Hospital, Kobe

Shinsuma General Hospital, Kobe

Osaka Saiseikai Nakatsu Hospital, Osaka

Oita Oka Hospital, Ōita

Keio University Hospital, Tokyo

Toho University Medical Center Ohashi Hospital, Tokyo

Tokyo Medical University Hospital, Tokyo

Tokyo Women's Medical University, Tokyo

113-8603

Nippon Medical School Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT02501018 - Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) | Biotech Hunter | Biotech Hunter